Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated oncology company developing diagnostic tests for the early detection of cancer, proprietary small molecules drugs not only to treat cancer but also to block metastasis and developing novel antibodies for therapeutic and diagnostic uses. AXIM is also developing new cannabinoid molecules for oncological therapeutics.
Currently, AXIM's subsidiary, Sapphire Biotech, Inc.’s, diagnostic tool is being used to study the company's enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells. Learn more here. For more information, please visit www.AXIMBiotech.com.
45 ROCKEFELLER PLAZA, 20TH FL
NEW YORK, NY 10111, USA
AXIM® Biotechnologies Files for Patent for Unique Biomarker for Early Detection of Cancer in BloodAXIM® Biotechnologies announced that its oncology-focused subsidiary, Sapphire Biotech, Inc., has filed a utility patent application relating to a novel biomarker for the detection of cancer in blood serum and urine. The patent application is based on Sapphire’s discovery of the long splice variant of the enzyme, quiescin sulfhydryl oxidase (QSOX1-L), as a biomarker in bladder cancer patients’ sera that was highly specific for the presence of cancer and was low or non-existent in normal donors’ sera. This is the first time that a clinically relevant QSOX1-L splice variant has been identified as a unique biomarker of bladder cancer and other cancers in serum.
UPLOAD NEW PRESS RELEASE (log in required)
Log in to upload press releases
AXIM BIOTECH Q&A
If you have any questions about AXIM Biotech or any of their products, please post them here.